-

Shareholder Alert: Robbins LLP Announces That An Investor of Golar LNG Limited (GLNG) Filed a Class Action Complaint Against the Company

SAN DIEGO & BERMUDA--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that an investor of Golar LNG Limited (NASDAQ: GLNG) filed a class action against the Company for alleged violations of the Securities Exchange Act of 1934 between April 30, 2020 and September 24, 2020.

If you suffered a loss due to Golar's misconduct, click here.

Golar LNG Limited (GLNG) Accused of Misleading Shareholders

On September 17, 2020, Golar announced the initial public offering of Hygo Energy Transition Ltd. ("Hygo"), a joint venture between Golar and investment vehicles associated with Stonepeak Infrastructure Partners. Just a week later, on September 24, 2020, media reported that Hygo's CEO was involved in a bribery network investigated as part of Brazil's Operation Car Wash, a large money laundering investigation. On this news, Golar's share price fell 32% to close at $6.86 per share on September 24, 2020, injuring investors.

An investor has now filed a lawsuit accusing Golar of misleading shareholders. Among other things, it alleges that Golar's filings with the SEC were misleading when they claimed Golar "adopted a Corporate Code of Business Ethics and Conduct that applies to all our employees" and that Corporate Code of Business Ethics and Conduct "expressly prohibits the offering, the giving, the solicitation or the acceptance of any bribe…"

If you purchased shares of Golar LNG Limited (GLNG) between April 30, 2020 and September 24, 2020, you have until November 23, 2020, to ask the court to appoint you lead plaintiff.

Contact us to learn more
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Golar settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:GLNG
Release Versions
English
$Cashtags
$GLNG
Hashtags
#ClassAction
#Finance
#Investment
#Investor
#Lawsuit
#Securities
#Shareholder
#Shareholderrights
#StockAlert
#StockMarketData
#StockNews
#StockTrading
#Stocks
#Trader
#shareholderrightslawfirm

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom